Pharma pulls together for Ebola vaccine; JnJ invests $200m

Producing a safe and effective Ebola vaccine as quickly as possible is "absolutely not an economic objective" for the biopharmaceutical industry at the moment, said Johnson & Johnson's Dr Paul Stoffels, chief scientific officer and worldwide chairman of pharmaceuticals, whose company just invested another $200m to speed production of its prime-boost shot, which the firm's Crucell unit is developing with Bavarian Nordic (BN) and the US government.